Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures

2012 ◽  
Vol 54 (5) ◽  
pp. 996-1003 ◽  
Author(s):  
Therese Högfeldt ◽  
Abeer A. Bahnassy ◽  
Anna Kwiecinska ◽  
Anders Österborg ◽  
Katja Pokrovskaja Tamm ◽  
...  
Keyword(s):  
Infectious Disease ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Gene Signatures ◽  
Inflammatory Gene ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Selin Merdan ◽  
Kritika Subramanian ◽  
Turgay Ayer ◽  
Johan Van Weyenbergh ◽  
Andres Chang ◽  
...  
Keyword(s):  
Gene Expression ◽  
T Cells ◽  
B Cell ◽  
Risk Prediction ◽  
Expression Profiling ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Gene Signatures ◽  
Large B Cell Lymphoma ◽  
Large B Cell

AbstractThe clinical risk stratification of diffuse large B-cell lymphoma (DLBCL) relies on the International Prognostic Index (IPI) for the identification of high-risk disease. Recent studies suggest that the immune microenvironment plays a role in treatment response prediction and survival in DLBCL. This study developed a risk prediction model and evaluated the model’s biological implications in association with the estimated profiles of immune infiltration. Gene-expression profiling of 718 patients with DLBCL was done, for which RNA sequencing data and clinical covariates were obtained from Reddy et al. (2017). Using unsupervised and supervised machine learning methods to identify survival-associated gene signatures, a multivariable model of survival was constructed. Tumor-infiltrating immune cell compositions were enumerated using CIBERSORT deconvolution analysis. A four gene-signature-based score was developed that separated patients into high- and low-risk groups. The combination of the gene-expression-based score with the IPI improved the discrimination on the validation and complete sets. The gene signatures were successfully validated with the deconvolution output. Correlating the deconvolution findings with the gene signatures and risk score, CD8+ T-cells and naïve CD4+ T-cells were associated with favorable prognosis. By analyzing the gene-expression data with a systematic approach, a risk prediction model that outperforms the existing risk assessment methods was developed and validated.

scholarly journals Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions

2016 ◽  
Vol 12 (4) ◽  
pp. 2782-2788 ◽  
Author(s):  
Therese Högfeldt ◽  
Crystal Jaing ◽  
Kevin Mc Loughlin ◽  
James Thissen ◽  
Shea Gardner ◽  
...  
Keyword(s):  
Infectious Disease ◽  
B Cell ◽  
Differential Expression ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract 3184: Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease region

2014 ◽  
Author(s):  
Ali Moshfegh ◽  
Therese Högfeldt ◽  
Crystal Jaing ◽  
Joachim Lundahl ◽  
Anders Osterborg ◽  
...  
Keyword(s):  
Infectious Disease ◽  
B Cell ◽  
Differential Expression ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Disease Region ◽  
Large B Cell

Fatal primary diffuse large B-cell lymphoma of the maxillary sinus initially treated as an infectious disease in an elderly patient: A clinicopathologic report

Gerodontology ◽  
2018 ◽  
Vol 35 (1) ◽  
pp. 59-62 ◽  
Author(s):  
Mayara Santos de Castro ◽  
Cínthia Magalhães Ribeiro ◽  
Marina Lara de Carli ◽  
Alessandro Antônio Costa Pereira ◽  
Felipe Fornias Sperandio ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Elderly Patient ◽  
B Cell ◽  
Maxillary Sinus ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas

2013 ◽  
Vol 55 (5) ◽  
pp. 1158-1165 ◽  
Author(s):  
Therese Högfeldt ◽  
Per Johnsson ◽  
Dan Grandér ◽  
Abeer A. Bahnassy ◽  
Anna Porwit ◽  
...  
Keyword(s):  
Infectious Disease ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Signal Transducer ◽  
Large B Cell Lymphoma ◽  
Transcription 3 ◽  
Large B Cell

Abstract #844: Pituitary Mass with Anterior Hypopituitarism from Metastatic Diffuse Large B Cell Lymphoma

2017 ◽  
Vol 23 ◽  
pp. 185-186
Author(s):  
Christine Lee ◽  
Kjersti Kirkeby
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Pituitary Mass ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document